Iradimed Co (IRMD)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $1.09B
Last updated: Nov 17, 2026 at 11:05 AM ET
Iradimed Co (IRMD) P/E Ratio & Valuation History
Iradimed (IRMD) trades at 43.5x trailing earnings and 12.1x sales. Its P/E of 43.5x is above its 5-year median of 34.6x. Its forward P/E is 35.6x. The median P/E across 8 similar companies is 13.6x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 22.2% higher over the next year. Its free cash flow yield is 2.4%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 43.5x |
| Forward P/E | 35.6x |
| Price to sales | 12.1x |
| Price to book | 10.2x |
| EV/EBITDA | 31.2x |
| Price to FCF | 41.7x |
| EV/FCF | 39.3x |
| PEG | 4.5 |
| FCF yield | 2.4% |
Historical Medians
Against its 10-year medians, its P/E is 21.8% above 35.7x, its P/S is 37.5% above 8.8x and its P/B is 52.2% above 6.7x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 43.5x | 34.6x | 35.7x |
| P/S | 12.1x | 9.4x | 8.8x |
| P/B | 10.2x | 8.0x | 6.7x |
Valuation History
Over the 10 year ends shown, its P/E ranged from 15.9x in 2016 to 72.1x in 2017.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $97.28 | 50.7x | 14.8x | 13.2x |
| 2024 | $55.00 | 34.2x | 9.5x | 8.1x |
| 2023 | $47.47 | 32.1x | 9.1x | 8.5x |
| 2022 | $28.29 | 26.0x | 6.7x | 4.8x |
| 2021 | $46.21 | 55.7x | 13.7x | 8.1x |
| 2020 | $22.80 | 55.6x | 8.8x | 4.6x |
| 2019 | $23.38 | 27.2x | 7.0x | 5.2x |
| 2018 | $24.46 | 45.3x | 8.9x | 7.1x |
| 2017 | $15.15 | 72.1x | 7.2x | 5.4x |
| 2016 | $11.10 | 15.9x | 3.8x | 4.1x |
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About IRMD
What is IRMD's forward P/E ratio?
Iradimed has a forward P/E ratio of 35.6x.
Is IRMD stock overvalued?
GNG's valuation label for IRMD is Fairly valued. Its P/E of 43.5x compares with a median of 13.6x across 8 similar companies.
What is IRMD's price to sales ratio?
Iradimed has a price to sales ratio of 12.1x.
What is Iradimed's average P/E ratio over 5 years?
Iradimed's median P/E over the last 5 years is 34.6x, from 60 month-end values through Oct 2026.
What is IRMD's PEG ratio?
Iradimed has a PEG ratio of 4.5.
IRMD pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts